Novel antidotes for target specific oral anticoagulants

Target specific oral anticoagulants (dabigatran, rivaroxaban, apixaban, and edoxaban) are changing the landscape of anticoagulation. The major drawback is the absence of an effective antidote for severe bleedings and/or prior to procedures. Currently there are a few promising antidotes undergoing cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Das, Arundhati, Liu, Delong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570637/
https://www.ncbi.nlm.nih.gov/pubmed/26380149
http://dx.doi.org/10.1186/s40164-015-0020-3
_version_ 1782390232820219904
author Das, Arundhati
Liu, Delong
author_facet Das, Arundhati
Liu, Delong
author_sort Das, Arundhati
collection PubMed
description Target specific oral anticoagulants (dabigatran, rivaroxaban, apixaban, and edoxaban) are changing the landscape of anticoagulation. The major drawback is the absence of an effective antidote for severe bleedings and/or prior to procedures. Currently there are a few promising antidotes undergoing clinical trials. This review summarized the latest development in idarucizumab, andexanet alpha and PER977.
format Online
Article
Text
id pubmed-4570637
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-45706372015-09-16 Novel antidotes for target specific oral anticoagulants Das, Arundhati Liu, Delong Exp Hematol Oncol Review Target specific oral anticoagulants (dabigatran, rivaroxaban, apixaban, and edoxaban) are changing the landscape of anticoagulation. The major drawback is the absence of an effective antidote for severe bleedings and/or prior to procedures. Currently there are a few promising antidotes undergoing clinical trials. This review summarized the latest development in idarucizumab, andexanet alpha and PER977. BioMed Central 2015-09-15 /pmc/articles/PMC4570637/ /pubmed/26380149 http://dx.doi.org/10.1186/s40164-015-0020-3 Text en © Das and Liu. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Das, Arundhati
Liu, Delong
Novel antidotes for target specific oral anticoagulants
title Novel antidotes for target specific oral anticoagulants
title_full Novel antidotes for target specific oral anticoagulants
title_fullStr Novel antidotes for target specific oral anticoagulants
title_full_unstemmed Novel antidotes for target specific oral anticoagulants
title_short Novel antidotes for target specific oral anticoagulants
title_sort novel antidotes for target specific oral anticoagulants
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570637/
https://www.ncbi.nlm.nih.gov/pubmed/26380149
http://dx.doi.org/10.1186/s40164-015-0020-3
work_keys_str_mv AT dasarundhati novelantidotesfortargetspecificoralanticoagulants
AT liudelong novelantidotesfortargetspecificoralanticoagulants

Ejemplares similares